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1. Introduction 
Liver microcirculation means that the blood circulation is sinusoids as a center, from the end 
branch of portal vein and hepatic artery through sinusoids to central vein in the liver. Liver 
microcirculation has two characteristics. One character is there are two import systems from 
portal vein and hepatic artery. Another is sinusoids with unique structure. All blood vessels 
which diameters are less 300m are part of microcirculation system. These vessels are able 
to regulate the blood flow and distribution.1 
Sinusoids are a capillary bed which is major place for regulation of blood and exchange of 
material in the liver. Sinusoids are constituted by microvasculature, sinusoid endothelial 
cellsȐSECȑ, Kupffer cells ȐKCȑand hepatic stellate cellsȐHSCȑ. 2 SEC and HSC are 
considered as cellular factors for regulation of sinusoids blood flow. HSC is located in 
perisinusoids with functions include storing Vitamin A, and controlling the diameter and 
blood flow of sinusoids by its pseudopods around sinusoids.3 SEC, KC and HSC all have 
contractility because they contain fiber, microvasculature and contractile protein.2  
The liver complex functions, which are biological synthesis, metabolism, detoxify and host 
defense, are tightly dependent perfect liver microcirculation.4 It is showed that failure of liver 
microcirculation is a general pathological alteration in chronic hepatitis and liver cirrhosis 
because changed construction of microvasculature, capillarization of sinusoid (the collagen is 
filled in perisinusoids) and compression of fibrous tissue. Generally, stenosis of sinusoid will 
lead to increase of resistence, decrease of blood flow rate and flow volume, and formation of 
portal hypertension. It is indicated that after hepatitis B virus infection, platelets were recruited 
to the liver, and their activation correlated with severely reduced sinusoidal microcirculation, 
delayed virus elimination and increased immunopathological liver cell damage.5 
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In normal condition, liver microcirculation is regulated by 3 ways. (1) SEC is a regulator of 
blood flow in the liver. The liver injury will lead to injury of SEC, reduction of fenestrae in 
SEC, straitens of sinusoid within accumulation of erythrocytes and formation of 
microthrombus. Injury and necrosis of SEC are major causes of disorder of liver 
microcirculation. (2) KC can also regulate the liver blood flow by its pseudopod inner of 
sinusoid. Actived KC may lead stenosis of sinusoid due to conglutination of leukocytes.6 (3) 
HSC is able to directly regulate contraction of sinusoids in normal liver. Active HSC has 
stronger character of contraction with increased concentration of Ca2+. HSC is just located in 
the site of sinusoid contraction. Propotional relationship has been proved between 
contraction of HSC and activation of HSC both in vivo and in vitro.7,8  Many chemical 
compounds are as inductors to induce contraction of HSC. They are included Endothelin-1 
(ET-1), Angiotensin II and vasopressin. ET-1 is concerned a strongest cytokine to induce 
contraction of HSC. Perfusion of ET-1 through portal vein leads to contraction of sinusoids. 
However, the compounds of NO, CO and adrenal medullar hormone have the functions to 
against ET-1-stimulated contraction of HSC. Contraction of active HSC (myofibroblast cell), 
which locates in fibrous septum in cirrhotic liver, can change construction of hepatic lobule 
and lead to increase resistens of microcirculation in the liver.  
Once failure of microcirculation in the liver, some symptoms and signs of patient are similar 
“blood stasis” in Traditional Chinese Medicine. Those are twinge in inside right flank or rib, 
hepatomegaly or splenomegaly, dim complexion, accompanied with spider nevi and liver 
palms, deep-red tongue, ecchymosis, taut or thready pulse. Some Chinese herb medicine, 
which is able to promote blood circulation to remove blood stasis, can prevent esophageal 
variceal bleeding on cirrhotic patients with portal hypertension, improve liver 
microcirculation and decrease portal hypertension through treating cirrhotic rats in vivo and 
inhibit contraction of active HSC in vitro in resent 10 years.9 
Fuzheng Huayu Capsule (FZHYC), a traditional Chinese medicine recipe, has demonstrated 
the effect of anti-fibrosis and reduced portal vein pressure in patients with chronic hepatitis 
B.10 Fuzheng means supporting the healthy energy. Huayu means dispersing blood stasis. 
The recipe is composed by 6 herbs those are Dan Shen (Radix Salviae Miltiorrhizae), Chong 
Cao (Paecilomyces hepiali Chen & Dai), Tao Ren (Semen Persicae), Jiao Gu Lan (Gynostemma 
pentaphyllum), Song Hua Fen (Pinus armandii Franch) and Wu Wei Zi (Fructus Schisandrae 
Chinensis). FZHYC has been used in numerous studies in China and has been found to have 
a satisfactory prophylaxis effect on the chronic liver injury and hepatic fibrosis in rats and 
humans. In addition, it enhances hepatic fibrolysis.11 
2. The clinical research 
2.1 Aims 
To elucidate the role of FZHYC in the prevention of esophageal variceal bleeding on 
cirrhotic patients with portal hypertension.  
2.2 Methods 
In a multi-center randomized and placebo-controlled trial, 146 cirrhotic patients, whose age 
range was between 18 and 70 years old, with esophageal varices were enrolled. According 
to the degree of esophageal and gastric varices, patients were stratified as 2 levels: small 
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level, and moderate and severe level. The randomization code was generated by SAS 
software for each subject. For patients with small varices, the trial was double blinded. The 
patients were randomly assigned to 2 groups: Patients were treated with FZHYC in FZHYC 
group or received placebo in control group. For patients with moderate and severe varices, 
the trial was single blind. They were divided into 3 groups: FZHYC group in which patients 
were treated with FZHYC, propranolol group in which patients were treated with 
Propranolol and combination group in which patients received both FZHYC and 
propranolol. The dose of FZHYC was 15 capsules (0.3g per capsule) per day and orally 
administrated at 3 times. The placebo was composed of stir-fried wheat powder with an 
identical-appearance in the aspects of dosage, color of the contents and packaging. The 
clinical intervention period lasts 2 years and the follow up would stop once the end points 
occur. The primary end point was esophageal or gastric variceal bleeding. 
2.3 Results  
2.3.1 In patients with small varices level 
A total of 6 patients reached the primary end point of esophageal variceal bleeding: 1 of 29 
patients in the Fuzheng Huayu group and 5 of 27 patients in the control group. The actuarial 
probability of remaining free of esophageal variceal bleeding was a significant different 
between 2 groups (96.3% vs. 77.01%, P=0.0422) (Fig. 1). Some patients with small varices 
were willing to be re-examined by endoscopy after treatment and small varices was 
dispared in several patients. There was a significant difference of esophageal varices degree 
in FZHYC group compared to the control group (P=0.014). (Tab. 1 and Fig. 2). 
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Fig. 1. Actuarial probability of remaining free of esophageal variceal bleeding in cirrhotic 
patients with small varices level. The patients were treated with Fuzheng Huayu Capsule in 
FZHYC group or placebo in control group for 24 months. Actuarial probability of remaining 
free of esophageal variceal bleeding was higher in FZHYC group than in controls (P<0.05). 
Follow-up (months)
FZHYC group 
Follow-up 
(months) 
Control group 
Follow-up 
(months) 
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Groups n No varicesジnス No changesジnス Enlarged varicesジnス 
FZHYC * 15 8 5 2 
control  9 1 3 5 
Note: compared with control group,*: P=0.014 
Table 1. Difference of developing small varices in FZHYC group and in controls after 24 
months 
 
Fig. 2. Alteration of small varices by endoscopy examination at pre and post treatment of 
FZHYC. Arrow shows the small varices in a cirrhotic patient at pre treatmtnt (left). The 
small varices, however, was disappeared in same patient at post treatmtnt (right). 
2.3.2 In patients with moderate and severe varices level 
5 patients in FZHYC group (n=30), 8 patients in Propranolol group (n=30) and 3 patients in 
the combination group (n=30) had esophageal variceal bleeding during their follow-up. 
Compared to the Propranolol group (56.99%), there were significant differences in the 
actuarial probability of remaining free of esophageal variceal bleeding in FZHYC group 
(76.13%, P＝0.0131) and the combination group (87.55%, P＝0.0086). Remaining free of 
variceal bleeding has a higher trend in combination group, but there was no significant 
difference between combination group and FZHYC group (P＝0.3876) (Fig.3).  
2.4 Summary 
FZHYC could effectively reduce the risk of esophageal variceal bleeding for cirrhotic 
patients with varices; especially the combination of the capsule and Propranolol delivered a 
better effect. The capsule could reduce the varices size in patients with small ones. 
3. The experiment in vivo 
For studying the mechanism of Fuzheng Huayu Capsule on prevention of esophageal 
variceal bleeding, we performed several experiments. Radix Salviae Miltiorrhizae is a major 
herb medicine in Fuzheng Huayu Recipe. Salvianolic-acid B (SA-B), which was extracted 
from Radix Salviae Miltiorrhizae, has been demonstrated to inhibit proliferation and functions 
of HSC in vitro 12and anti-fibrosis in vivo.13 We did lot of work to deal with how Fuzheng 
Huayu Recipe and SA-B relieves portal hypertension. 
post treatment pre treatment 
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Fig. 3. Actuarial probability of remaining free of esophageal variceal bleeding in cirrhotic 
patients with moderate and severe varices level The patients were treated with Fuzheng 
Huayu Capsule in FZHYC group, Propranolol in Propranolol group, or hoth in combination 
group for 24 months. Actuarial probability of remaining free of esophageal variceal bleeding 
was higher in combination group and FZHYC group than in Propranolol group. Compared 
with Propranolol group, the difference was significant in combination group (P<0.01) and in 
FZHYC group (P<0.05). Although the probability was higher in combination group than in 
FZHYC group, but the difference was not significant. 
3.1 Experiment 1: Chinese herb medicine can decrease portal vein pressure in 
cirrhotic rats 
3.1.1 Aims 
To investigate effect of Fuzheng Huayu Recipe and SA-B on decreasing portal vein pressure 
in cirrhotic rats. 
3.1.2 Methods 
3.1.2.1 Establishment of liver cirrhosis model 
The Sprague-Dawley male rats were randomly divided into model group (n=46) and normal 
group (n=14).The rats in model group were administrated intraperitoneally with 0.5% 
dimethylnitrosamine (DMN) at a dose of 2ml/kg body weight for 3 consecutive days and 
interval 4 days per week. The treatment was for 4 weeks. The rats in normal group were 
administrated intraperitoneally with physiological salin at a dose of 2ml/kg body weight 
for same duration. 
3.1.2.2 Grouping animals and drug administration 
After molding, two rats were randomly sacrificed to observe pathological changes of the 
liver tissue. The rats in model group were randomly more divided into 3 groups, control 
Follow-up (months) 
Combination group 
Propranolol group 
FZHYC group 
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group (n=13), Fuzheng Huayu (FZHY) group (n=15) and the SA-B group (n=16), once liver 
cirrhosis was confirmed. The rats in the FZHY group were gavaged with extractor of 
Fuzheng Huayu Recipe. The content of extractor equals 36.9g crude drug per 100ml. The 
rats in the SA-B group were gavaged with SA-B solution (125mg per 100ml). 
Simultaneously, the rats in control group and normal group were gavaged with water. All 
dose of gavage was 1ml/100g body weight, once per day, for 3 weeks.         
3.1.2.3 Measurement of portal vein pressure 
The rats were anesthetized with 2% sodium pentobarbital (2ml/kg body weight) in the end 
of experiment. One PE-10 tube filling with heparin was inserted from superior mesenteric 
vein into portal vein and then connected with pressotransducer to measure pressure. 
Enterocoelia was exposed totally after mesurement. If ascites was found, dry cotton ball was 
used to blot liquid and then it was weighted for measurement of ascites. Serum separated 
from blood which was taken in the vena cava was used for liver function detection. The 
sample of liver tissue, which was 1.0cm0.8cm0.3cm, was fixed by formalin, embedded by 
paraffin, and cutted for 4µm thick for HE and collagen staining. Moreover, 100mg liver 
tissue was used to detect hydroxyproline (Hyp). 
3.1.3 Result 
3.1.3.1 Investigating death and ascites in the rats  
During making hepatic cirrhosis model, there were no dead rats in week 4 but the death 
started in week 5. Until the end of week 7, there was still no death in normal group but there 
were 4 dead rats in control group, 2 dead rats both in FZHY group and in SA-B group, 
respectively. The reason that leads to death was liver failure. The number of the rats with 
ascites was most in control group than in other groups. The difference was significantly. 
(Tab. 2) 
 
Groups n Deathジnス Ascitesジnス 
normal 14 0 0 
control 13 4 6 
FZHY 
SA-B 
15 
16 
2 
2 
 1* 
 0* 
Note: compared with control group, *: P<0.05 
Table 2. The situation of death and ascites in cirrhotic rats in each group 
3.1.3.2 Observation of Pathology of liver in rats  
3.1.3.2.1 Inflammation was reduced by Chinese herb medicine in the liver of cirrhotic rats 
The structure of liver lobule was clear, hepatocytes arranged as cords radially from central 
vein to the periphery and a few connective tissue was observed in the portal area in normal 
group. At the end of treatment, pathological alteration was observed in the liver that was 
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large bleeding area, a lot of swell or necrotic hepatocytes, a lot of infiltrating inflammatory 
cells including lymphocytes and mononuclears, distorted sinusoids and obviously widened 
portal areas in controls. They were varying decreased that was degeneration or necrosis of 
hepatocytes, and intrahepatic hemorrhage both in FZHY group and in SA-B group 
compared with controls. (Fig. 4) 
3.1.3.2.2 Hepatic fibrosis was reversed by Chinese herb medicine 
A little collagen fibers located only in portal areas or surrounded central veins in normal rat 
liver. Increased fibrous tissue formed thick interval that invaded into the hepatic lobules and 
moved round to form pseudolobules with different size in controls’liver. The fibrous 
intervals were thinner both in FZHY group and SA-B group than in controls. It means that 
hepatic fibrosis was reversed by FZHY recipe and SA-B. (Fig. 5) 
3.1.3.2.3 The liver function of cirrhotic rats can be improved by Chinese herb medicine 
Compared with normal rats, it was significantly increased in controls that are the activity of 
serum ALT and AST, serum level of TBiLȐP<0.01 and P<0.05ȑbut meanwhile the 
concentration of serum Alb were significantly decreasedȐP<0.05ȑ. However, they were 
obviously lower both in FZHY group and SA-B group than in controls that are the activity 
of serum ALT and ASTȐP<0.01ȑ, and serum level of TBiLȐP<0.05ȑ. The concentration of 
serum Alb were back to normal level with significantly difference compared with controls 
(P <0.05). (Fig. 6) 
 
 
 
 
 
Fig. 4. Fuzheng Huayu Recipe and SA-B could relieve inflammation and structure damage 
in the liver tissue of DMN model rats A: normal group, B: control group, C: FZHY group 
and D: SA-B group. The staining was by HE (200). 
A B 
C D 
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Fig. 5. Fuzheng Huayu Recipe and SA-B could relieve collagen fiber deposition in the liver 
tissue of DMN model rats A: normal group, B: control group, C: FZHY group, and D: SA-B 
group. The staining was by Sirius red (200)  
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Fig. 6. Fuzheng Huayu Recipe and SA-B could decrease the avtivity of serum ALT and AST, 
and serum level of TBiL, but increase serum concentration of Alb in DMN model rats  
normal group, n=14; control group, n=9; FZHY group, n=13; SA-B group, n=14. 
3.1.3.2.4 The concentration of Hyp in the liver tissue of cirrhotic rats was decreased by 
Chinese herb medicine 
Compared with normal group, concentration of Hyp in the liver tissue was significantly 
increased at the end of experiment in controls (P<0.01). The concentration of Hyp, however, 
was significantly lower both in FZHY group and SA-B group than in controls (P<0.05). (Fig. 7) 
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Fig. 7. Fuzheng Huayu Recipe and SA-B could decrease concentration of Hyp in the liver 
tissue of DMN model rats A. normal group, n=12; control group, n=9; FZHY group, n=12. B. 
normal group, n=13; control group, n=9; SA-B group, n=12. 
3.1.3.2.5 Portal vein pressure of the cirrhotic rats was declined and the tissue 
concentration of ET-1 was dropped by Chinese herb medicine 
The portal vein pressure of control rats was significantly increased in the end of 
experiment compared with normal rats (P<0.01). The increased range was up to 8mmHg. 
The portal pressure，however, was significantly lower in the rats treated with FZHY 
Recipe or SA-B than controls (P<0.05). (Fig. 8) The hepatic tissue concentration of ET-1 
was obviously higher in controls than in normal group (P<0.01). But concentration of ET-1 
was remarkably declined in FZHY group and SA-B group compared with controls 
(P<0.05). (Fig. 9.) 
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Fig. 8. Fuzheng Huayu Recipe and SA-B could decrease portal vein pressure in DMN model 
rats  normal group, n=12; control group, n=9; FZHY group, n=13; SA-B group, n=14. 
 
 
 
Fig. 9. Fuzheng Huayu Recipe and SA-B could decrease content of ET-1 in the liver tissue of 
DMN model rats normal group, n=14; control group, n=9; FZHY group, n=13; SA-B group, 
n=14. 
3.1.4 Summary 
The elevation of portal vein pressure is positively correlated with the increase of ET-1 
concentration in the liver tissue during the process of liver cirrhosis. FZHY Recipe and SA-B 
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can dramatically decrease the cirrhosis-induced elevation of portal vein pressure and 
concentration of ET-1 in the liver tissue through their effect on anti-fibrosis in the liver. 
3.2 Experiment 2: Chinese herb medicine can relieve capillarization of sinusoid in 
cirrhotic rats 
3.2.1 Aims 
To investigate the effects of FZHY Recipe on capillarization of hepatic sinusoids. 
3.2.2 Methods 
32 Sprague-Dawley male rats, weighing about 150g, were randomly divided into normal 
group (n=7) and model group (n=25). The modeling mathod was the same as Experiment 1 
for making cirrhosis. The cirrhotic rats were more randomly divided into control group 
(n=11), and FZHY group (n=14). The drug, dose and method of administration for each 
group were the same as Experiment 1, too. But the duration of treatment was for 4 weeks. 
Rat’s blood, under etherization condition, was collected from inferior vena cava, and was 
separated to serum. The sample of liver (1.0cm×0.8cm×0.3cm) was immediately taken and 
fixed in neutral formalin, embedded in paraffin, sectioned at 5 m thick. The sections of 
liver were stained with HE, Masson and immunohistochemistry. Three rats were randomly 
selected from each group respectively for observation of hepatic microstructure. The each 
liver sample was cut to a 1 mm3 cube, fixed with 2.5% glutaraldehyde and 1% osmium 
tetroxide for 2h, embedded with araldite 618, and cut to ultrathin sections. The sections were 
observed by the electron microscope (H-600). 100mg liver tissue was used to detect Hyp. 
3.2.3 Results 
3.2.3.1 Fuzheng Huayu Recipe had the potent effect against hepatic fibrosis of the model 
rat 
It was observed that hemorrhage, necrosis and extensive connective tissue hyperplasia in 
the liver tissues of model rats. The fiber septa reached out its branches towards the liver 
lobule. (Fig. 10 and Tab. 3) The level of hydroxyproline was significantly increased. 
Compared with controls, liver inflammation, necrosis of hepatocytes and hepatic fibrosis 
was reduced in FZHY group. The concentration of liver hydroxyproline was significantly 
lower in FZHY group than in controls (P<0.05). (Tab. 4) 
 
Groups n 
Hyperplasia degree of collagenous fibers 
0 + ++ +++ ++++ 
normal 7 7 0 0 0 0 
controls 11 0 1 1 4 5 
FZHY * 14 0 0 8 4 2 
Note: compared with controls, *: U=4.06, P<0.01 
Table 3. Hyperplasia degree of collagenous fibers in each group 
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Fig. 10. Fuzheng Huayu Recipe inhibited hepatic fibrosis The liver sections were stained 
with Masson and showed hepatic fibrosis. A: Fibrous septa (arrows indicated) and 
pseudolobule (arrow’s head indicated) have formed in controls. B: Fibrous septa (arrow 
indicated) is less and pseudolobule is absent in FZHY group (100×). 
 
Groups n Hyp(μg/g liver wet weight) 
normal 7 112.37±11.93 
controls 11 292.83±36.78* 
FZHY 14 215.03±75.46# 
Note: compared with normal, *: P<0.05; compared with controls, #: P<0.05 
Table 4. Liver Hydroxyproline level in liver tissues ( x ±s) 
3.2.3.2 Fuzheng Huayu Recipe could effectively inhibit sinusoid capillarization in fibrotic 
rats 
It was observed that the structure of sinusoids is clearly and the phenotype of SEC is thin by 
microscopy in normal group. There were many fenestrae in SEC cytoplasm and no 
basement membrane covered on SEC in perisinusoid side. In controls, the sinusoids were 
twisted and narrow, the fenestrae in SEC were reduced or disappeared, and basement 
membrane was observed. (Fig.11)Factor Ⅷ related antigen (Ⅷ R·Ag), -smooth muscle actin 
(-SMA) and laminin (LM), the important indexes for hepatic sinusoid capillarization, were 
positive staining in liver tissure. But collagen type Ⅳ (Col Ⅳ), which is a composition of 
functional membrane but not a composition of basement membrane, expressed majorly in 
fibrous septa and HSC but less and discontinuously in perisinusoids in controls. Compared 
with controls, however, the narrow sinusoids were reduced and some sinusoids returned to 
normal phenotype, basement membrane looked discontinuous thiner, and the positive 
degree of Ⅷ R·Ag, -SMA and LM were lower and their positive area was significantly 
smaller by image analysis in the liver of FZHY group than in that of controls (P<0.05). Col Ⅳ 
expressed still continuously in perisinusoids in FZHY group. It indicated that the normal 
structure of sinusoids was most kept and it meansed that the alteration of hepatic sinusoid 
capillarization was reversed. (Fig.12) 
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Fig. 11. Fuzheng Huayu Recipe could inhibit sinusoid capillarization by observation of 
electron micrographs S: sinusoid; C: collagen. A: Hepatic sinusoid appeare as a typical 
capillary surrounded by continuous basement membrane. (arrow’s heads indicated) in the 
liver of fibrotic rat. The perisinusoid is stenosis (arrows indicated) and microvilli of 
hepatocyte are almost absent in the space (15000×). B: Sinusoid capillarization is not formed 
in the liver of rat treated with Fuzheng Huayu Recipe. The fenestrae are observed (arrow’s 
heads indicated) in cytoplasm of SEC. A mass of microvilli of hepatocyte stretchs into 
perisinusoid is exist (arrow indicated) but basement membrane is absent (10000×).   
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Fig. 12. Fuzheng Huayu Recipe could alter the express of indexes for hepatic sinusoid 
capillarization by immunohistochemistry staining in fibrotic liver of rats Arrows show the 
positive area. A: Ⅷ R·Ag is around the vessels with strong staining in controls. B: The positive 
area of Ⅷ R·Ag is decreased in FZHY group. C: Col Ⅳ expresses majorly in fibrous septa and 
HSC but less and discontinuously in perisinusoids in controls. D: Col Ⅳ expresses almost 
continuously in perisinusoids in FZHY group. E: The express of LM is observed on the wall of 
vessels and sinusoids in the liver of controls. F: The express of LM is only observed on the wall 
of vessels in the liver of FZHY group. G: -SMA expresses strongly in perisinusoids, HSC and 
fibous septa in controls. H: -SMA expresses dramaticlly less in FZHY group (100×). 
3.2.4 Summary 
Fuzheng Huayu Recipe had the potent effect on against liver fibrosis. The one of 
mechanisms of the recipe perhaps is associated with inhibition of hepatic sinusoid 
capillarization. 
3.3 Experiment 3: SA-B could decrease portal vein pressure in rats induced by ET-1 
3.3.1 Aims 
To establish a rat model of portal hypertension induced by ET-1 and investigate the effect of 
SA-B on decreasing portal vein pressure in the model. 
3.3.2 Methods 
3.3.2.1 To establish portal hypertension model of rats induced by ET-1 
48 Sprague-Dawley male rats were randomly divided into four groups: the NS solution 
group, the ET-1 low-dose group (0.3g/kg body weight), the ET-1 medium-dose group 
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(1.0g/kg body weight) and the ET-1 high-dose group (3.0g/kg body weight). Rats were 
injected with 200l NS solution into rat via femoral vein by a pump with a rate of 80μl/min 
in NS solution group. As the same method, rats were injected with 200ml ET-1 solution with 
the dose of 0.3g/kg body weight, 1.0g/kg body weight or 3.0g/kg body weight 
respectively in 3 ET-1 groups. Then, monitored the changes of carotid pressure and portal 
vein pressure in each group at 2min, 4min, 6min, 8min, 10min, 15min, 20min, 25min and 
30min after injection. 
3.3.2.2 To treat rats with drugs in portal hypertension models 
20 Sprague-Dawley male rats with about 330g body weight were randomly divided into 
four groups: normal group, SA-B group, BQ-123 (ETAR antagonist) group and BQ-788 (ETBR 
antagonist) group (n=5 in each group). In normal group, BQ-123 group and BQ-788 group, 
rats were gavaged with water at a dose of 1ml/100g body weight and rats in SA-B group 
were gavaged with SA-B solution (containing 125mg/100ml) at the same dose. The gavage 
was performed twice per day for 5 days. The experiment started at 1 hour after the final 
gavage. First, via rat’s femoral vein, rats was injected with BQ-123 (12.5µg/kg body weight) 
in BQ-123 group and with BQ-788 (15µg/kg body weight) in BQ-788 group. 30min later, rats 
were injected with a dose (3µg/kg body weight) of ET-1 solution by a pump with rate of 
80μl/min in each group. Then, the portal vein pressure was measured before and after 
injection of ET-1. 
3.3.2.3 To measure carotid pressure, heart rate and portal vein pressure 
A piece of PE-50 tube, which full with heparin solution, was inserted into the left carotid 
artery of the rat. Following that, connect the tube to a pressure transducer in order to 
measure carotid pressure and heart rate. Then a piece of PE-10 tube, which full with heparin 
solution, was inserted from superior mesenteric vein to the middle of portal vein.  Connect 
the tube to a pressure transducer for measurement of portal vein pressure. 
3.3.3 Results 
3.3.3.1 A kind of model of rat with portal hypertension was successfully established by 
injection of ET-1  
There was no obvious effect of solution volume on carotid pressure and portal vein pressure 
after injection of NS solution. ET-1 solution with equal volume of NS solution was injected 
into the rats in low- and medium-dose groups. The carotid pressure was not noticeable rise 
or fall, only minor fluctuations within 20 min after injection. The carotid pressure, however, 
was increased slightly after injection of ET-1 in high-dose group but the alteration was not 
significant (Fig.13). Portal vein pressure was increased in short time after injection of ET-1 
although the alteration was not same in three different dose groups. The alteration of 
pressure was most remarkable in high-dose group than in others. After reaching to peak 
level, portal vein pressure was stable for 4min, 4min and 10min in low-, medium- and high-
dose groups, respectively (Fig.14 and Tab. 5). The results indicated that the increase of portal 
vein pressure was solely caused by the injection of ET-1 and without related with the 
volume of solution in this kind of animal model. This inducing method would not cause a 
significant increase of systemic blood pressure. Compared with the existing portal vein 
perfusion model, this kind of portal hypertension model is more similar to the "living" state. 
It was also avoided that increase of portal vein pressure caused by sudden increase of partial 
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blood volume by quickly direct injection of ET-1 in portal vein. This kind of model would 
better reflect the true effect of ET-1 compared with other kind of model. Therefore, this kind of 
model could use not only for investigation of efficacy and mechanism of drug, but also 
provided an ideal experimental subject for screening drugs to treat portal hypertension. 
 
                                                NS group                                                                     low-dose group 
 
                                           medium-dose group                                                        high-dose group 
Fig. 13. Effect of ET-1 with different doses on rat carotid pressures After detecting carotic 
pressure for 5min, NS solution or ET-1 with same volume but different doses were 
constantly injected and carotic pressure was detected for 30min. The pressure was not 
increased during detected time in NS group, and low- and medium-dose groups. But the 
carotid pressure was increased slightly in high-dose group. 
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0
20
40
60
80
100
120
140
160
0 5 7 9 11 13 15 20 25 30 35
Ca
ro
ti
d 
pr
es
su
re
˄
mm
Hg
˅
Time (min)
0
20
40
60
80
100
120
140
160
0 5 7 9 11 13 15 20 25 30 35Po
rt
al
 v
ei
n 
pr
es
su
re
(m
mH
g)
Time˄min˅
0
20
40
60
80
100
120
140
160
0 5 7 9 11 13 15 20 25 30 35
Ca
ro
ti
d 
pr
es
su
re
˄
mm
Hg
˅
Time (min)
0
20
40
60
80
100
120
140
160
0 5 7 9 11 13 15 20 25 30 35C
ar
ot
id
 p
re
ss
ur
e
(m
mH
g)
Time˄min˅
0
2
4
6
8
10
0 5 7 9 11 13 15 20 25 30 35Po
rt
al
 v
ei
n 
pr
es
su
re
˄
mm
Hg
˅
Time (min)
0
2
4
6
8
10
0 5 7 9 11 13 15 20 25 30 35Po
rt
al
 v
ei
n 
pr
es
su
re
(m
mH
g)
Time˄min˅
www.intechopen.com
Traditional Chinese Medicine  
Can Improve Liver Microcirculation and Reduce Portal Hypertension in Liver Cirrhosis 111 
  
                                        medium-dose group                                                          high-dose group 
Fig. 14. Effect of ET-1 with different doses on rat portal vein pressure After detecting portal 
vein pressure for 5min, NS solution and ET-1 with same volume but different doses were 
constantly injected and portal vein pressure was detected for 30min. There was no obvious 
effect of NS solution on portal vein pressure. The pressure was increased at 5min when 
starting injection of ET-1 and kept high level for 4min, 4min and 10min in low-, medium- 
and high-dose groups after the pressure reaching to a peak level at 9 min, respectively. 
 
Groups n Initial pressure
Highest 
pressure 
Increased range 
  (mmHg) (mmHg) (mmHg) 
NS 8 6.6±0.3 6.5±0.4 -0.1±0.2 
low-dose 10 6.1±0.8 7.5±0.8** 1.3±0.3 
medium-dose 10 6.3±0.5 8.1±0.6** 1.8±0.5## 
high-dose 9 6.0±0.6 8.5±0.9** 2.5±0.5##ۼۼ 
Note: compared with the initial pressure in the interior-group, **: P<0.01; compared with NS group, 
: P<0.001; compared with low-dose group, ##: P<0.01; compared with medium-dose group, ۼۼ: 
P<0.01 
Table 5. Effect of ET-1 with different doses on portal vein pressure of rats (X±S) 
 
Groups n Initial pressure Highest pressure Increased range 
  (mmHg) (mmHg) (mmHg) 
control 5 6.1±0.7 8.6±1.1*** 2.5±0.4 
SA-B 5 6.1±0.7 7.8±1.6** 1.6±0.5## 
BQ-123 5 5.9±1.1 7.1±1.0 1.2±0.2### 
BQ-788 5 5.9±0.9 6.9±1.1 0.98±0.5### 
Note: compared with initial pressure interior-group, **: P<0.01, ***: P<0.001; compared with the 
controls, ##: P<0.01, ###: P<0.001 
Table 6. Effect of SA-B, BQ-123 or BQ-788 on reducining portal vein pressure of rats induced 
by ET-1 (X±S) 
3.3.3.2 SA-B could inhibit the rise of portal vein pressure in rats induced by ET-1 
Portal vein pressur significantly increased after ET-1 solution (3μg/kg body weight) was 
injected to rats pretreated with water by gavage. Although portal vein pressure of the rats, 
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which were pretreated with SA-B solution by gavage or with BQ-123 or BQ-788 by injection, 
was also increased after ET-1 injection, however, the ranget-increased was obviously less 
than that in controls (P<0.01, P<0.001) (Tab.6). Furthermore, the stable time, when portal 
vein pressure kept high level after reaching peak level, was short in SA-B group. It was just 
6 min in SA-B group but was 10min in controls. (Fig. 15)  
 
 
 
 
Fig. 15. SA-B could inhibit portal vein pressure of rats induced by ET-1 Portal vein pressure 
began increase at 5min when starting injection of ET-1. The peak level of pressure was at 
9min in SA-B group. Then the pressure kept high level until to at 15min.  In controls, 
however, the pressure continuously increased until to highest peak level at 15min and 
began to decrease. The pressure level was still hinger (a little bit higher than a peak level in 
SA-B group) until to at 25min. 
 
Groups n 
Carotid artery 
pressure 
Heart rate 
  (mmHg) (Beats/min) 
control 3 130.9±13.2 439±21 
SA-B 5 145.6±10.1 439±21 
Table 7. Compare of the carotid artery pressure and heart rate in SA-B group and controls 
3.3.3.3 SA-B did not affect on carotid pressure and heart rate in normal rat 
Rats were pretreated with SA-B solution by gavage for 5d, but the carotid pressure and 
heart rate were no significant different between in SA-B group and controls. (Tab.7) 
3.3.4 Summary 
A kind of rat model of portal hypertension is successfully established by injection of ET-1. 
SA-B can down regulate the raised portal vein pressure by antagonizing the effect of 
extraneous ET-1. 
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3.4 Experiment 4: SA-B can decrease portal vein pressure in mice induced by ET-1 
3.4.1 Aims 
To establish portal hypertension model of mice induced by ET-1 and investigate the effect of 
SA-B on decreasing portal vein pressure in this kind of model. 
3.4.2 Methods 
3.4.2.1 To establish a kind of portal hypertension model mice induced by ET-1 
36 male Kunming mices, 30±5g body weight, were randomly divided into three groups: 
control group (n=12), SA-B group (n=12) and blocker group (n=12). Mice were gavaged with 
SA-B (1mg/ml) in SA-B group and gavaged with water in control group and blocker group. 
The volume of gvage was 0.5 ml per mouse once a day for 3days.  Mice were injected with 
BQ-123Ȑ2g/kg body weightȑby tail vein at 0.5h before start of below experiment in 
blocker group. 
Mice were injected with ET-1Ȑ1.6g/kg body weightȑat constant velocity by tail vein. 6 
mice were randomly taken out from each group to measure blood flow volume in liver 
microcirculation using a laser-Doppler flow instrument before and after injection of ET-1. 
Other 6 mice in each group were measured the blood flow rate in liver microcirculation by 
an inverted fluorescence microscope with microscopic live video technology before and 
after injection of ET-1.  
3.4.2.2 To measure the average blood flow volume in the perfusion of liver 
microcirculation 
Each mouse was injected with 2% pentobarbital sodium solution at a dose of 2ml/kg body 
weight for anesthesia. After opening abdomen the liver was put on a detector connected 
with a laser-Doppler flow instrument to record the blood flow volum in the perfusion of 
liver microcirculation for 5min. After a pause, ET-1 was injected by a syringe pump at a 
constant rate of 80l/ min through tail vein. Then, the blood flow volum was recorded again 
for 5min.  The average blood flow volume was calculated from the stable datas during the 
former 5min record and late 5min record, respectively.  
3.4.2.3 To measure the blood flow rate in liver microcirculation 
Each mouse was injected with 2% pentobarbital sodium  solution at a dose of 2ml/kg 
body weight for anesthesia. After opening abdomen the liver was put on a piece of glass 
plate which was on an inverted fluorescence microscope. After 0.05ml pre-labeled 
erythrocytes with FITC was injected into the inferior vena cava, a suitable site was 
focused to observe the liver microcirculation. Some FITC-RBCs were observed to be 
moving quickly in microvasculature or sinusoids and recorded with digital video. ET-
1(1.6g /kg body weight) was injected by a syringe pump at a constant rate of 80l/ min 
through tail vein of mouse then moving FITC-RBCs were immediately recorded again 
with digital video. The moving range of FITC-RBCs in record was calculated by the 
analytic software to compare the differences of blood flow rate in liver microcirculation in 
3 groups. 
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3.4.3 Results 
3.4.3.1 SA-B reduced average blood flow volume in liver microcirculation 
The blood flow volume in liver microcirculation was decreased in 3 groups after injection of 
ET-1. The reduced range was smaller in SA-B group and in block group than in controls 
(P<0.01).  (Tab. 8) 
3.4.3.2 SA-B reduced average blood flow rate in liver microcirculation 
The blood flow rate in liver microcirculation was significantly decreased after injection of 
ET-1 (P<0.01). But the reduced range was smaller in SA-B group and in blocker group than 
in controls (P<0.05 and P<0.01). (Tab. 9) 
 
Average blood flow volume in liver microcirculation㸦BPU㸧 
Groups n 
Before ET-1 
injection 
After ET-1 
injection 
Reduced range 
control 6 1186.83±41.14 1060.50±18.33 126.33±27.51 
SA-B 6 1269.50±59.90 1189.33±40.33 80.17±20.30 ** 
blocker 6 202.00±36.54 1131.00±23.67 71.00±12.82 ** 
Note: compared with the controls, **: P<0.01 
Table 8. SA-B and BQ-123 could inhibit reduction of average blood flow volume in mice 
induced by ET-1 (X ± S) 
 
Blood flow rate in liver microcirculation㸦mm/s㸧 
Groups n 
Before ET-1 
injection 
After ET-1 
injection 
Reduced range 
Control 6 0.60±0.01 0.36±0.02ۼۼ 0.23±0.02 
SA-B 6 0.62±0.04 0.39±0.01ۼۼ 0.18±0.04 * 
blocker 6 0.60±0.05 0.43±0.01ۼۼ 0.17±0.05 ** 
Note: compared with initial blood flow rate,ۼۼ: P<0.01; compared with controls, *: P<0.05，**: P<0.01   
Table 9. SA-B and BQ-123 could inhibit reduction of the liver blood flow rate in mice 
induced by ET-1 (X ± S). 
3.4.4 Summary 
The average blood flow volume and blood flow rate in mice liver microcirculation were 
reduced by extraneous ET-1. SA-B could inhibit the effect of ET-1 to improve liver 
microcirculation.  
4. The experiment in vitro 
It is believed that recipe of herb medicine is not suitable for research of mechanism in vitro. 
For more studying the mechanism of Fuzheng Huayu Recipe on reducing portal 
hypertension, we can only select SA-B as investigated subject in vitro. 
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4.1 Aims 
To investigate the effects of SA-B on inhibiting contraction of human HSC induced by ET-1. 
4.2 Methods 
4.2.1 To observe contraction of HSC 
Human HSC was isolated from the normal section of transplant patients’liver by enzymatic 
digestion and density-gradient centrifugation with Nycodenz solution.14. Passaged HSC was 
planted on the collagen gel which was pre-poured into 12-wells plates. After cells had 
adhered, HSC was divided into 5 groups: 1) serum-free group in which HSC was cultured 
with serum-free M199; 2) ET group in which HSC was treated with ET-1(10 -8 mol/L); 3) 
low-dose group in which HSC was treated with ET-1 and 10-7mol/L SA-B; 4) medium-dose 
group in which HSC was treated with ET-1 and 10-6mol/L SA-B; 5) high-dose group in 
which HSC was treated with ET-1 and 10-5mol/L SA-B. The edge of the gel was scraped out 
wall of the well by a syringe needle after adding drugs. The diameter of gel was observed at 
2h, 4h, 6h, and 12 h during HSC culture and a gel image analysis system was used to 
calculate the area of gel. The area of gel can indicate the contractibility of HSC. The 
experiment was repeated for 3 times. 
4.2.2 To detect the concentration of free calcium ([Ca2+]i) in HSC 
HSC was planted in 6-wells plates. Flu-3/AM was added into media with final 
concentration of 5μmol/L. Then HSC was in a incubator with 37℃, 5%CO2-95% humid air 
and dark for 30min. HSC was washed twice with serum-free M199 for moving the dye and 
divided into 5 groups as above. HSC in each group was observed under a laser confocal 
microscope before and after adding relevant drugs. The observation conditions were Kr/Ar 
laser, excitation wavelength 488nm, emission wavelength 505-530nm. The experiment was 
repeated 2 times.    
4.3 Results  
4.3.1 SA-B inhibited contraction of HSC induced by ET-1 
Area of gel was significantly bigger in low-dose group (2209.02±177.96μm2), medium-dose 
group (2164.95±111.84μm2) and high-dose group (2374.73±218.38μm2) than in ET group 
(156.23±102.16m2). The statistical difference was dramatically (P<0.01). But there was no 
obviously difference among in 3 SA-B treatment groups. (Fig. 16) The morphological 
changes of HSC showed dose-dependent after incubation with SA-B. The phenotype of HSC 
in low-dose group was similar to that in ET group. The phenotype of HSC in high-dose 
group was similar to that in serum-free group. The phenotype of HSC in medium-dose 
group was between the low- and high-dose groups. (Fig. 17)  
4.3.2 SA-B suppressed the intracellular concentration of [Ca2+]i in HSC induced by ET-1 
Compared with ET group in which fluorescence of HSC was very strong, [Ca2+]i 
fluorescence image appeared the opposite phenomenon in 3 SA-B treatment groups. Only a 
few cells appeared slightly enhanced fluorescent and the intracellular concentration of 
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[Ca2+]i was obviously lower in 3 SA-B treatment groups than in ET group. The intracellular 
concentration of [Ca2+]i was weak and only two relative low-lying peaks were in low-dose 
group within 120sec. The alteration of intracellular concentration of [Ca2+]i was smaller in 
medium-dose group and high-dose group during observation. (Fig.18). The results 
indicated that one of mechanisms of SA-B on inhibiting contraction of HSC may be related 
with that SA-B suppressed the intracellular concentration of [Ca2+]i in HSC.  
 
 
 
 
Fig. 16. SA-B could inhibit contraction of human HSC a: serum-free group; b: ET group; c: 
low-dose group; d: medium-dose group; e: high-dose group. Human HSC was cultured on 
collangen gel. Actived HSC are able to contract to lead to area of gel becoming small. In 
serum-free group, contraction capacity of HSC was weak so that the area of gel was nearly 
invariant. Active HSC induced by ET-1 contracted strongly. The area of gel was significantly 
smaller in ET group than in serum-free groups. SA-B could inhibit contraction of HSC 
induced by ET-1. The area of gel was bigger in 3 SA-B treatment groups than in ET group. 
Groups 
ۻۻ  ۻۻ ۻۻ 
ۼۼ 
ۻۻ VS model group       P<0.01 
ۼۼ VS serum-free group P<0.01 
a 
b 
c 
d
e
medium-dose
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Fig. 17. The morphological changes of HSC in each group a: serum-free group; b: ET group; 
c: low-dose group; d: medium-dose group; e: high-dose group. HSC grew exuberantly on 
gel and the pseudopodium of HSC was a lot, thin and long in serum-free group. After 
induced by ET-1 for 12h, however, HSC became obviously small with contraction. The 
quantity and the pseudopodium of HSC was decreased in ET group. The phenotype of HSC 
in low-dose group was similar to that in ET group. The phenotype of HSC in high-dose 
group was similar to that in serum-free group. The phenotype of HSC in medium-dose 
group was between the low- and high-dose groups (By OLYMPUS I × 50 / I × 70 inverted 
system microscope, Japan, 200×). 
A B 
C D 
E 
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Fig. 18. SA-B suppressed the intracellular concentration of [Ca2+]i in HSC Fluorescent of Flu-
3/AM which represents the intracellular concentration of [Ca2+]i was observed. The 
expression of fluorescent in HSC was very stronger in ET group than in serum-free group. 
But the expression of fluoresent in HSC was dose-dependent in 3 SA-B treatment groups. 
The higher the dose of SA-B was, the weaker expression of fluorescent was (By Zeiss510 
laser confocal microscope, German, 200×). 
            Groups: 
                    serum-free   ET 
 
                       low-dose    medium-dose 
 
                    high-dose 
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5. Conclusion  
The Chinese medicine, Fuzheng Huayu Recipe, is able to reduce portal hypertension in liver 
cirrhosis both in clinic and in vivo. The effect of Fuzheng Huayu Recipe is related with 
reversing hepatic fibrosis and capillarization, and decreasing concentration of ET-1 in the 
liver tissue. SA-B is an extracted component of Fuzheng Huayu Recipe. Several studies 
showed that the effect in SA-B was similar to Fuzheng Huayu Recipe on reversing hepatic 
fibrosis and decreasing concentration of ET-1 in the liver tissue. SA-B inhibited contraction 
of HSC through suppressing the intracellular concentration of [Ca2+]i. Based on above 
effects, intrahepatic vessel resistance was reduced which leaded to improve liver 
microcirculation. It has distinctively character that Chinese herb medicine is used to treat 
hepatic portal hypertension which is caused by failure of liver microcirculation in chronic 
liver diseases.  
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modern data about molecular mechanisms of pathogenesis of portal hypertension in liver cirrhosis, the
information about the original predictor of risk of bleeding from gastro-esophageal varices and new methods
for their conservative treatment.
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